BIIB34:BVMF
Biogen
184,49 BRL
0,00%
(0,00) 1D
5-окт., 15:59:13 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
32,39 млд
Avg. vol.
7,00
Volume
0,00
52-wk high
191,00 BRL
52-wk low
128,69 BRL
Shares outstanding
147,75 млн
No. of employees
8 миң
Mkt. cap
32,39 млд
Avg. vol.
7,00
Volume
0,00
52-wk high
191,00 BRL
52-wk low
128,69 BRL
Shares outstanding
147,75 млн
No. of employees
8 миң
News stories
From web sources and news partners
AD HOC NEWS
·
14 саат мурун
Biogen stock heads toward October 28 results after 1.69 percent gain
Pluang
·
18 саат мурун
Biogen expected to slightly beat Q3 earnings wi...
Proactive financial news
·
1 күн мурун
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen
CEOChris Viehbacher
Employees7,5 миң
Founded1978
HeadquartersКембридж, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitebiogen.com